EP1572103A2 - Verwendungen von il-6-antagonisten gegen die angiogenese - Google Patents

Verwendungen von il-6-antagonisten gegen die angiogenese

Info

Publication number
EP1572103A2
EP1572103A2 EP03783264A EP03783264A EP1572103A2 EP 1572103 A2 EP1572103 A2 EP 1572103A2 EP 03783264 A EP03783264 A EP 03783264A EP 03783264 A EP03783264 A EP 03783264A EP 1572103 A2 EP1572103 A2 EP 1572103A2
Authority
EP
European Patent Office
Prior art keywords
angiogenesis
mammal
monoclonal antibody
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03783264A
Other languages
English (en)
French (fr)
Other versions
EP1572103A4 (de
Inventor
Mohit Trikha
Zhao Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP1572103A2 publication Critical patent/EP1572103A2/de
Publication of EP1572103A4 publication Critical patent/EP1572103A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
EP03783264A 2002-11-15 2003-11-10 Verwendungen von il-6-antagonisten gegen die angiogenese Withdrawn EP1572103A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42690102P 2002-11-15 2002-11-15
US426901P 2002-11-15
PCT/US2003/035651 WO2004045507A2 (en) 2002-11-15 2003-11-10 Anti-angiogenic uses of il-6 antagonists

Publications (2)

Publication Number Publication Date
EP1572103A2 true EP1572103A2 (de) 2005-09-14
EP1572103A4 EP1572103A4 (de) 2008-02-13

Family

ID=32326451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03783264A Withdrawn EP1572103A4 (de) 2002-11-15 2003-11-10 Verwendungen von il-6-antagonisten gegen die angiogenese

Country Status (5)

Country Link
EP (1) EP1572103A4 (de)
JP (1) JP2006516957A (de)
AU (1) AU2003290682A1 (de)
CA (1) CA2506230A1 (de)
WO (1) WO2004045507A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
JP5191235B2 (ja) 2005-10-21 2013-05-08 中外製薬株式会社 心疾患治療剤
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
JP2009521909A (ja) 2005-12-30 2009-06-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ＩＬ−６とＩＬ−６Ｒαの複合体のｇｐ１３０への結合を阻害する抗ＩＬ−６抗体
AR059213A1 (es) 2006-01-27 2008-03-19 Univ Keio Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
WO2008019061A2 (en) 2006-08-03 2008-02-14 Vaccinex, Inc. Anti-il-6 monoclonal antibodies and uses thereof
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
WO2009014263A1 (ja) 2007-07-26 2009-01-29 Osaka University インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
CN101918452A (zh) * 2007-11-15 2010-12-15 中外制药株式会社 与Anexelekto结合的单克隆抗体及其利用
CN102256623A (zh) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
JP6049455B2 (ja) * 2009-05-18 2016-12-21 ザ ユニバーシティ オブ ホンコンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｈｏｎｇ Ｋｏｎｇ 炎症性関節炎を治療するための組成物および方法
NZ598127A (en) * 2009-07-31 2014-03-28 Shin Maeda Cancer metastasis inhibitor
DK2578231T3 (da) 2010-05-28 2022-12-12 Chugai Pharmaceutical Co Ltd Antitumor-t-celle-reaktionsforstærker
SG10201608703SA (en) * 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
EP2898896A1 (de) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
MA51554A (fr) * 2014-11-07 2020-11-18 Sesen Bio Inc Anticorps il-6 améliorés
AU2018214554C1 (en) 2017-02-01 2022-12-15 Novo Nordisk A/S Treatment of diuretic resistance
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CA3087699A1 (en) 2018-01-05 2019-07-11 Corvidia Therapeutics, Inc. Methods for treating il-6 mediated inflammation without immunosuppression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036061A2 (en) * 1997-02-13 1998-08-20 The Victoria University Of Manchester Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
WO2000078815A1 (en) * 1999-06-24 2000-12-28 Applied Molecular Evolution ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69525971T3 (de) * 1994-12-29 2013-01-10 Chugai Seiyaku K.K. Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998036061A2 (en) * 1997-02-13 1998-08-20 The Victoria University Of Manchester Reducing fibrosis and/or scarring by inhibiting interleukin-6 receptor-mediated activity
WO2000078815A1 (en) * 1999-06-24 2000-12-28 Applied Molecular Evolution ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
D. WENDLING ET AL.: "Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody." JOURNAL OF RHEUMATOLOGY, vol. 20, February 1993 (1993-02), pages 259-262, XP000972960 *
H. VAN ZAANEN ET AL.: "Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study." BRITISH JOURNAL OF HAEMATOLOGY, vol. 102, 1998, pages 783-790, XP002986057 *
J-Y. BLAY ET AL.: "Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma." INTERNATIONAL JOURNAL OF CANCER, vol. 72, 1997, pages 424-430, XP002461200 *
K. YOSHIZAKI ET AL.: "Therapy of rheumatoid arthritis by blocking IL-6 signal transduction with a humanized anti-IL-6 receptor antibody." SPRINGER SEMINARS IN IMMUNOPATHOLOGY, vol. 20, 1998, pages 247-259, XP001069950 *
P. SMITH ET AL.: "Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice." PROSTATE, vol. 48, 2001, pages 47-53, XP003012696 *
See also references of WO2004045507A2 *

Also Published As

Publication number Publication date
WO2004045507A2 (en) 2004-06-03
AU2003290682A1 (en) 2004-06-15
WO2004045507A3 (en) 2006-01-26
EP1572103A4 (de) 2008-02-13
JP2006516957A (ja) 2006-07-13
CA2506230A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
WO2004045507A2 (en) Anti-angiogenic uses of il-6 antagonists
CN1829740B (zh) 结缔组织生长因子抗体
AU2004231159B8 (en) Vascular endothelial cell growth factor antagonists and uses thereof
DE60118186T2 (de) Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
AU2006227571B2 (en) Novel anti-PlGF antibody
US20090028862A1 (en) Emmprin antagonists and uses thereof
US20050100550A1 (en) Anti-angiogenic uses of IL-6 antagonists
CA2560903A1 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
US20050031615A1 (en) Method of inhibiting tumor growth with anti-tissue factor antibodies
US20050214302A1 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050614

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20060405BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/00 20060101ALI20071218BHEP

Ipc: A61P 35/04 20060101ALI20071218BHEP

Ipc: A61P 35/00 20060101ALI20071218BHEP

Ipc: A61K 39/395 20060101AFI20060405BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20080111

17Q First examination report despatched

Effective date: 20080806

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081217